| Ytd | 30.84% | |
| 1y | -13.85% |
| Open | 2.63 | Prev Close | 2.63 | Low | 2.59 | High | 2.83 | Mkt Cap | 47.74M |
| Vol | 250.05K | Avg Vol | 2.01M | EPS | -0.65 | P/E | N/A | Forward P/E | -2.23 |
| Beta | -0.46 | Short Ratio | 13.35 | Inst. Own | 42.04% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 04-28 | Earning | 08-10 | 50-d Avg | 2.62 | 200-d Avg | 2.49 | 1yr Est | 3.40 |
VERU News
Veru Inc. (VERU) Q3 2026 Earnings Call Transcript
Veru (NASDAQ:VERU) reported quarterly losses of $(0.30) per share which beat the analyst consensus e
-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight
-- When issued U.S. patent protection until at least October 2044 -- -- Allowed patent adds to alrea
MIAMI, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biophar
MIAMI, FL, July 30, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biophar
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing inno
-- Phase 2b PLATEAU clinical trial exceeds targeted full enrollment of 200 patients — -- Interim ana
MIAMI, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biophar
https://www.sec.gov/ix?doc=/Archives/edgar/data/863894/000143774926019478/veru20260601_8k.htm
Oppenheimer analyst Leland Gershell maintains Veru (NASDAQ:VERU) with a Outperform and lowers the
Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript
Veru (NASDAQ:VERU) reported quarterly losses of $(0.12) per share which beat the analyst consensus e
--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on tr
MIAMI, FL, May 06, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharm
Veru Inc. (NASDAQ: VERU - Get Free Report)'s stock price crossed below its 200-day moving average du
Veru Inc. (NASDAQ: VERU - Get Free Report) shares passed below its 200-day moving average during tra
https://www.sec.gov/Archives/edgar/data/863894/000119312526145576/d84893ds3.htm
Veru Inc. (NASDAQ: VERU - Get Free Report)'s stock price passed below its 200-day moving average dur
-- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, an
-- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bo
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript
Veru (NASDAQ:VERU) reported quarterly losses of $(0.26) per share which beat the analyst consensus e
Veru (NASDAQ: VERU - Get Free Report) and Flora Growth (NASDAQ: FLGC - Get Free Report) are both sma
MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biophar
Canaccord Genuity analyst Edward Nash initiates coverage on Veru (NASDAQ:VERU) with a Buy rating
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
MIAMI, FL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biophar
Veru Inc. (NASDAQ: VERU - Get Free Report) shares passed below its 200-day moving average during tra
Investors are prepping for this week's earnings reports which include homebuilders, several appa
Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innov
Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innov
Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innov
On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimag